[1] [1] SHAO L, LI P, YE J, et al. Risk of gastric cancer among patients with gastric intestinal metaplasia[J]. International Journal of Cancer, 2018, 143(7): 1671-1677.

[2] [2] MARI L, MILANO F, PARIKH K, et al. A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia[J]. Cell Reports, 2014, 7(4): 1197-1210.

[3] [3] LI T, GUO H, LI H, et al. MicroRNA-92a-1-5p increases CDX2 by targeting FOXD1 in bile acids-induced gastric intestinal metaplasia[J]. Gut, 2019, 68(10): 1751-1763.

[4] [4] KAHLSON M A, DIXON S J. Copper-induced cell death[J]. Science, 2022, 375(6586): 1231-1232.

[5] [5] TSVETKOV P, COY S, PETROVA B, et al. Copper induces cell death by targeting lipoylated tca cycle proteins[J]. Science, 2022, 375(6586): 1254-1261.

[6] [6] LAI Y, LIN C, LIN X, et al. Identification and immunological characterization of cuproptosis-related molecular clusters in Alzheimer's disease[J]. Frontiers in Aging Neuroscience, 2022, 14: 932676.

[7] [7] FAVIER R P, SPEE B, PENNING L C, et al. Copper-induced hepatitis: the commd1 deficient dog as a translational animal model for human chronic hepatitis[J]. The Veterinary Quarterly, 2011, 31(1): 49-60.

[8] [8] QI X, WANG J, CHE X, et al. The potential value of cuprotosis (copper-induced cell death) in the therapy of clear cell renal cell carcinoma[J]. American Journal of Cancer Research, 2022, 12(8): 3947-3966.

[9] [9] CHENG B, TANG C, XIE J, et al. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis[J]. Life Sciences, 2023, 325: 121659.

[10] [10] WANG K, WANG M, LI Z, et al. Systematic analysis of the cuprotosis in tumor microenvironment and prognosis of gastric cancer[J]. Heliyon, 2023, 9(3): e13831.

[11] [11] YI J F, LI Y M, LIU T, et al. Mn-sod and cuzn-sod polymorphisms and interactions with risk factors in gastric cancer[J]. World Journal of Gastroenterology, 2010, 16(37): 4738-4746.

[12] [12] NEWMAN A M, LIU C L, GREEN M R, et al. Robust enumeration of cell subsets from tissue expression profiles[J]. Nature Methods, 2015, 12(5): 453-457.

[13] [13] LIVAK K J, SCHMITTGEN T D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−CT method[J]. Methods, 2001, 25(4): 402-408.

[14] [14] JONAITIS P, KUPCINSKAS L, KUPCINSKAS J. Molecular alterations in gastric intestinal metaplasia: 11[J]. International Journal of Molecular Sciences, 2021, 22(11): 5758.

[15] [15] FENG A, HE L, CHEN T, et al. A novel cuproptosis-related LncRNA nomogram to improve the prognosis prediction of gastric cancer[J]. Frontiers in Oncology, 2022, 12: 957966.

[16] [16] WANG Y, LIU K, SHEN K, et al. A novel risk model construction and immune landscape analysis of gastric cancer based on cuproptosis-related long noncoding RNAs[J]. Frontiers in Oncology, 2022, 12: 1015235.

[17] [17] BELITKIN D, PANT S M, MUNNE P, et al. Hepsin regulates tgf signaling via fibronectin proteolysis[J]. EMBO Reports, 2021, 22(11): e52532.

[18] [18] WITTIG BLAICH S M, KACPRZYK L A, EISMANN T, et al. Matrix-dependent regulation of AKT in hepsin-overexpressing PC3 prostate cancer cells[J]. Neoplasia, 2011, 13(7): 579-589.

[19] [19] ZHANG M, ZHAO J, TANG W, et al. High hepsin expression predicts poor prognosis in gastric cancer[J]. Scientific Reports, 2016, 6: 36902.

[20] [20] GAN Y, YE F, HE X X. The role of ywhaz in cancer: a maze of opportunities and challenges[J]. Journal of Cancer, 2020, 11(8): 2252-2264.

[21] [21] NISHIMURA Y, KOMATSU S, ICHIKAWA D, et al. Overexpression of ywhaz relates to tumor cell proliferation and malignant outcome of gastric carcinoma[J]. British Journal of Cancer, 2013, 108(6): 1324-1331.

[22] [22] BERGERON M J, CLMENON B, HEDIGER M A, et al. SLC13 family of Na+-coupled di- and tri-carboxylate/sulfate transporters[J]. Molecular Aspects of Medicine, 2013, 34(2/3): 299-312.

[23] [23] SHENG S, JIWEN W, DEXIANG Z, et al. DMBT1 suppresses progression of gallbladder carcinoma through PI3K/AKT signaling pathway by targeting PTEN[J]. Bioscience, Biotechnology, and Biochemistry, 2019, 83(12): 2257-2264.

[24] [24] BRAIDOTTI P, NUCIFORO P G, MOLLENHAUER J, et al. DMBT1 expression is down-regulated in breast cancer[J]. BMC Cancer, 2004, 4: 46.

[25] [25] DU J, GUAN M, FAN J, et al. Loss of dmbt1 expression in human prostate cancer and its correlation with clinical progressive features[J]. Urology, 2011, 77(2): 509.e9-e13.

[26] [26] GARAY J, PIAZUELO M B, LOPEZ CARRILLO L, et al. Increased expression of deleted in malignant brain tumors (DMBT1) gene in precancerous gastric lesions: findings from human and animal studies[J]. Oncotarget, 2017, 8(29): 47076-47089.

[27] [27] LEE B H, KIM N, LEE H S, et al. The role of CDX2 in intestinal metaplasia evaluated using immunohistochemistry[J]. Gut and Liver, 2012, 6(1): 71-77.